

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

DELAY IN DESPATCH OF THE CIRCULAR IN RELATION TO MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF BNCT EQUIPMENT THE PROVISION OF TECHNICAL ADVISORY SERVICE AND THE ACQUISITION OF BNCT PARTS

Reference is made to the announcement of China Biotech Services Holdings Limited (the “**Company**”) dated 23 June 2022 in relation to, among other matters, (i) the Sales Contract; (ii) the Service Contract; (iii) the MOU; and (iv) the Master Service Agreement (the “**Announcement**”). Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as ascribed to them in the Announcement.

As disclosed in the Announcement, a circular of the Company containing, among other matters, further details of the Sales Contract, the Service Contract, the MOU and other information as required under the GEM Listing Rules is expected to be despatched to the Shareholders on or before 15 July 2022.

Due to the outbreak of COVID-19 and the implementation of the COVID-19 prevention and control measures in the PRC and Hong Kong, the Company encounters difficulties in the receipt of the bank confirmations from the banks in the PRC and Hong Kong. Hence, additional time is required for the Company to prepare and finalise the financial information, including the statement of the sufficiency of working capital and the statement of indebtedness for inclusion in the circular. The Company hereby announces

that it has applied for, and the Stock Exchange has granted a waiver from the strict compliance with Rule 19.41(a) of the GEM Listing Rules (the “**Waiver**”) and an extension of the deadline for the despatch of the circular to a date on or before 25 August 2022. The Waiver applies to this case only, and the Stock Exchange may withdraw or change the Waiver if the Company’s situation changes.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 15 July 2022

As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun and Mr. Huang Song; one non-executive Director, namely, Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the Stock Exchange’s website at www.hkexnews.hk on the “Latest Listed Company Information” for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.